...Gilead denies requiring Indian generics companies, and their distributors, to collect and maintain records of all patients purchasing the drug in India, but says it has asked generic firms to take reasonable steps to deter large-scale “diversion” of the drug to other countries...Executives at Indian drugmakers say that Gilead had been pushing for strict surveillance over sofosbuvir use in India...Gilead has since softened its stance in India following “pushback” from activists and the generics companies themselves...